explore -WSS

explore

author：comprehensive 2025-10-02 21:07:21 - browse：835

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Syphilis numbers in the United States reach record heights

entertainment

WSS

Caribou posts encouraging results on off

Readout Newsletter: The latest on Novavax, Merck, Bluebird

There’s a way to spot data fakery. All journals should be using it

Philips to halt sales of sleep apnea machines in U.S.

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Syphilis numbers in the United States reach record heights

hotspot

explore

entertainment

Medicare details structure of new drug price negotiation program

Syphilis numbers in the United States reach record heights

Medical records are filled with copy

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Affirmative action in medical school literally saved lives

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

explore

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Medicare Advantage insurers face 0.2% cut to 2025 payments

Pancreatic cancer early detection could be helped by AI

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

New clues to why women have higher risk of autoimmune disorders

entertainment

leisure time

knowledge

hotspot